Table 1 FFP administered in relation to the three approaches to classifying the circumstances of administrationa
Variable | FFP units (median, first to third quartile) | FFP volume, ml (median, first to third quartile) | FFP dose, ml kg-1 (median, first to third quartile) |
|---|---|---|---|
Reason given by clinician at time of FFP transfusion | |||
   Coagulopathy with bleeding (n = 185) | 3 (2 to 4) | 875 (558 to 1104) | 11.1 (7.8 to 15.3) |
   Coagulopathy without bleeding (n = 138) | 2 (2 to 4) | 561 (509 to 854) | 8.9 (6.8 to 13.1) |
   No bleeding prior to procedure (n = 59) | 2 (2 to 4) | 560 (528 to 1017) | 9.8 (6.9 to 13.0) |
   P value for differences across groups | <0.0001 | <0.0001 | 0.009 |
   All (N = 404) | 3 (2 to 4) | 736 (536 to 1092) | 10.2 (7.0 to 14.1) |
Clinically significant haemorrhage recorded on day of transfusion | |||
   No (n = 215) | 2 (2 to 4) | 561 (517 to 1017) | 9.1 (6.7 to 13.2) |
   Yes (n = 189) | 3 (2 to 4) | 875 (558 to 1100) | 11.1 (7.9 to 14.7) |
   P value for differences across groups | <0.0001 | <0.0001 | 0.006 |
Use of FFP in relation to occurrence of PT prolongation during ICU admission | |||
FFP administered but no PT prolongation occurred at any time during ICU admission (n = 64) | 2 (2 to 4) | 568 (502 to 936) | 8.5 (5.7 to 12.6) |
PT prolongation occurred during ICU admission, but FFP administered out with an episode of PT prolongation (n = 63) | 2 (2 to 4) | 570 (535 to 1077) | 8.6 (6.3 to 13.7) |
FFP administered during an episode of PT prolongation (n = 277) | 3 (2 to 4) | 806 (542 to 1092) | 10.8 (7.3 to 14.4) |
P value for differences across groups | 0.11 | 0.037 | 0.014 |